Isis Helps Oxford Company Raise £3m to Commercialise Predictive Cancer Biomarkers
Treating only patients who are likely to benefit from anti-cancer drugs and identifying quickly which treatment is best for each person, is the aim behind a new spin-out from the University of Oxford, Oxford Cancer Biomarkers Limited (OCB).